DUAL MECHANISM OF ACTION (MOA)

IMPROVING OUTFLOW WHERE IT MATTERS MOST

Only VYZULTA
features nitric oxide
as part of its dual MOA1-3

plus

There are two key factors in chronic contraction of the TM:

  • Activation of Rho kinase8
  • Activation of calcium signaling9

Glaucomatous eyes have shown up to a 40% deficiency in nitric oxide, which is thought to play a role in chronic TM contraction, decreased outflow facility, and elevated IOP. Introduction of exogenous nitric oxide relaxes the meshwork and increases outflow.10-13

Only VYZULTA delivers nitric oxide to the primary pathway for increased aqueous humor outflow.1,14,15

TM function

The remaining aqueous humor exits the eye through a secondary route, the uveoscleral pathway.7

Latanoprost acid, delivered via VYZULTA, is a prostaglandin analog that increases interstitial space within the uveoscleral pathway to improve aqueous humor outflow and decrease IOP.1,5,14

Latanoprost acid function
video Thumbnail
Watch the mechanism of action for VYZULTA.
Eye Drop

SIGN UP TO RECEIVE UPDATES AND LEARN MORE ABOUT VYZULTA

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent
  • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation
  • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA should generally not be used in patients with active intraocular inflammation
  • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema
  • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients
  • Contact lenses should be removed prior to the administration of VYZULTA and may be reinserted 15 minutes after administration
  • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%)
PLEASE SEE FULL PRESCRIBING INFORMATION >

References: 1. VYZULTA Prescribing Information. Bausch & Lomb Incorporated. 2. Buys ES, Potter LR, Pasquale LR, Ksander BR. Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. Front Mol Neurosci. 2014;7:38. 3. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci. 2014;55(8):5005-5015. 4. Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 5. Johnson M, McLaren JW, Overby DR. Unconventional aqueous humor outflow: A review. Exp Eye Res. 2017;158:94-111. 6. Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014;30(2-3):102-109. 7. Cavet ME, DeCory HH. The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1-2):52-60. 8. Suzuki H, Kimura K, Shirai H, et al. Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration. Arterioscler Thromb Vasc Biol. 2009;29(2):217-224. 9. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channel. Am J Physiol Cell Physiol. 2008;294(6):C1378-C1386. 10. Doganay S, Evereklioglu C, Turkoz Y, Er H. Decreased nitric oxide production in primary open-angle glaucoma. Eur J Ophthalmol. 2002;12(1):44-48. 11. Galassi F, Renieri G, Sodi A, Ucci F, Vannozzi L, Masini E. Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. Br J Ophthalmol. 2004;88(6):757-760.. 12. Nathanson JA, McKee M. Alterations of ocular nitric oxide synthase in human glaucoma [published correction appears in Invest Ophthalmol Vis Sci 1995 Nov;36(12):2333]. Invest Ophthalmol Vis Sci. 1995;36(9):1774-1784. 13. Aliancy J, Stamer WD, Wirostko B. A review of nitric oxide for the treatment of glaucomatous disease. Ophthalmol Ther. 2017;6(2):221-232. 14. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Invest Ophthalmol Vis Sci. 2015;56(6):4108-4116. 15. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp Eye Res. 2011;93(3):250-255.

SEE MORE

INDICATION

VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION 
  • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent